|
| Criteria |
|
| Inclusion criteria |
| (1) 45–75 years of age without gender restriction |
| (2) Meet the diagnostic criteria of CHD |
| (3) Meet the diagnostic criteria of grade I–II angina |
| (4) Meet the diagnostic criteria of blood stasis |
| (5) Meet the diagnostic criteria of stable angina pectoris |
| (6) Take regular aspirin (enteric-coated) for at least one year (the incidence of bleeding events, adverse events (AEs), and adverse reactions will be noted) |
| (7) Calprotectin in stool is above 50 μg/g |
| (8) Before the study start, patients and their families are fully informed and voluntarily willing to sign an informed consent |
|
| Exclusion criteria |
| (1) Mental or physical disorders |
| (2) Pregnant, menstruating, and breastfeeding women |
| (3) Severe heart disease and severe cardiopulmonary dysfunction |
| (4) Severe primary diseases, such as cancer, liver and renal damage, and multiple organ failure |
| (5) Poorly controlled hypertension (>160/100 mmHg) |
| (6) Current participation in another clinical trial or participation in another clinical trial within three months |
| (7) Having underwent surgery within eight weeks |
| (8) Having drug allergy history or allergic constitution |
| (9) Diabetes |
| (10) Status epilepticus |
| (11) Unstable vital signs |
| (12) Combined with serious infection, infectious diseases |
| (13) Acute intestinal infection |
| (14) Unsuitability or poor compliance for this trial |
|
| Termination criteria |
| Participant termination |
| (1) Serious adverse events occur or having obvious abnormal value of the laboratory tests |
| (2) The investigators believe someone’s trial needs to be terminated because of medical, safety, or GCP considerations |
| Trial termination |
| (1) Half of the participants have mild adverse events other than gastrointestinal reactions |
| (2) The investigators believe it is necessary to abort the trial for medical or safety purposes |
|
